Dat Nguyen1,2,3, Micah M Lawrence1,2,3, Haley Berg3, Monika Aya Lyons1,2,3, Samir Shreim2, Mark T Keating2, John Weidling2, Elliot L Botvinick1,2,3,4. 1. Department of Biomedical Engineering, University of California Irvine, Irvine, California 92697-2730, United States. 2. Beckman Laser Institute and Medical Clinic, University of California Irvine, Irvine, California 92612, United States. 3. Edwards Lifesciences Foundation Cardiovascular Innovation and Research Center, University of California Irvine, Irvine, California 92697, United States. 4. Department of Surgery, University of California, Irvine, California 92697-2730, United States.
Abstract
Clinical research shows that frequent measurements of both pH and lactate can help guide therapy and improve patient outcome. However, current methods of sampling blood pH and lactate make it impractical to take readings frequently (due to the heightened risk of blood infection and anemia). As a solution, we have engineered a subcutaneous pH and lactate sensor (PALS) that can provide continuous, physiologically relevant measurements. To measure pH, a sheet containing a pH-sensitive fluorescent dye is placed over 400 and 465 nm light-emitting diodes (LEDs) and a filter-coated photodetector. The filter-coated photodetector collects an emitted signal from the dye for each LED excitation, and the ratio of the emitted signals is used to monitor pH. To measure lactate, two sensing sheets comprising an oxygen-sensitive phosphorescent dye are each mounted to a 625 nm LED. One sheet additionally comprises the enzyme lactate oxidase. The LEDs are sequentially modulated to excite the sensing sheets, and their phase shift at the LED drive frequency is used to monitor lactate. In vitro results indicate that PALS successfully records pH changes from 6.92 to 7.70, allowing for discrimination between acidosis and alkalosis, and can track lactate levels up to 9 mM. Both sensing strategies exhibit fast rise times (< 5 min) and stable measurements. Multianalyte in vitro models of physiological disorders show that the sensor measurements consistently quantify the expected pathophysiological trends without cross talk; in vivo rabbit testing further indicates usefulness in the clinical setting.
Clinical research shows that frequent measurements of both pH and lactate can help guide therapy and improve patient outcome. However, current methods of sampling blood pH and lactate make it impractical to take readings frequently (due to the heightened risk of blood infection and anemia). As a solution, we have engineered a subcutaneous pH and lactate sensor (PALS) that can provide continuous, physiologically relevant measurements. To measure pH, a sheet containing a pH-sensitive fluorescent dye is placed over 400 and 465 nm light-emitting diodes (LEDs) and a filter-coated photodetector. The filter-coated photodetector collects an emitted signal from the dye for each LED excitation, and the ratio of the emitted signals is used to monitor pH. To measure lactate, two sensing sheets comprising an oxygen-sensitive phosphorescent dye are each mounted to a 625 nm LED. One sheet additionally comprises the enzyme lactate oxidase. The LEDs are sequentially modulated to excite the sensing sheets, and their phase shift at the LED drive frequency is used to monitor lactate. In vitro results indicate that PALS successfully records pH changes from 6.92 to 7.70, allowing for discrimination between acidosis and alkalosis, and can track lactate levels up to 9 mM. Both sensing strategies exhibit fast rise times (< 5 min) and stable measurements. Multianalyte in vitro models of physiological disorders show that the sensor measurements consistently quantify the expected pathophysiological trends without cross talk; in vivo rabbit testing further indicates usefulness in the clinical setting.
pH and lactate are biomarkers that can be monitored
during sepsis
and liver and lung disease to improve patient outcome.[1−4] Blood pH is naturally buffered to within a range of 7.35 to 7.45
and deviations from this range can be indicative of serious disease.[4,5] Examples of these deviations are in cases of metabolic acidosis
and alkalosis where blood pH can change when the body has too high
or low concentration of hydrogen ions (H+) and/or bicarbonate.[4,5] A form of metabolic acidosis is lactic acidosis, which can occur
when lactate is generated in excess (hyperlactatemia, >2 mM) and
the
amount of circulating H+ exceeds the capacity of the blood’s
buffering system.[6,7] Elevated lactate levels are often
a sign of cellular hypoxia as lactate is excessively produced during
anaerobic glycolysis.[8] An increase in lactate
can result in a decrease in pH; however, this is not always the case.
For this reason, it is important to recognize that measuring only
lactate or pH is not a surrogate for measuring the other. For example,
in respiratory acidosis, pH may be directly influenced by an accumulation
of carbon dioxide in the blood, while lactate remains unchanged.[9] In this case, frequent pH measurements can guide
therapy. Importantly, there are a variety of circumstances when both
pH and lactate should be measured simultaneously. Frequently referenced
examples are during sepsis or septic shock as Lee et al. found that
both the lactate levels and pH are essential when predicting patient
mortality.[1]Current clinical standards
for measuring blood pH and lactate require
intermittent blood draws and analysis using benchtop instruments (Yellow
Springs Instrument, YSI) or hand-held monitors (Abbott Laboratories
i-STAT).[10−12] The frequency of measurements is limited ultimately
by the frequency of blood draws which increase the likelihood of blood
infections and anemia.[10,13] Meanwhile, there is substantial
evidence suggesting that attentive monitoring and treatment of pH
and lactate can improve patient prognosis and outcome.[14,15] In a multisite study with 348 patients having initial lactate ≥3.0
mEq/L, goal-oriented treatment targeting a 10% decrease in lactate
per hour increased patient survivability by 10% as compared to the
control (standard treatment, p = 0.067).[16] In addition to reduced mortality, patients were
discharged from the intensive care unit (ICU) earlier than those in
the control group. Moreover, in a prospective study with 75 patients
experiencing sepsis and metabolic acidosis, both pH and lactate endpoint
values were concluded as vital biomarkers toward patient outcome.[17] In this study, the 11 nonsurvivors had a lower
mean pH and a higher mean lactate level than survivors after 5 days
in the ICU. Changes in pH and lactate were not statistically significant
(p > 0.714) as compared to initial values for
the
nonsurvivors, whereas significant changes were observed for the 64
survivors (P < 0.002).[17] Monitoring pH and lactate clearly has major implications toward
patient prognosis, underscoring the value of a continuous pH and lactate
sensor.There are well-established pH sensing modalities including
electrochemical-based
electrodes and luminescent dyes. Electrochemical-based glass and metal
oxide electrodes measure pH through a difference in H+ concentration
between a sensitive and reference electrode.[18,19] Although glass electrodes provide the highest level of specificity,
they cannot be easily miniaturized and require frequent calibration.[19] Metal oxide electrodes can be easily miniaturized
but exhibit low resolution, large drift, and hysteresis.[18,20] Meanwhile, pH-sensitive luminescent probes vary in their linear
range of sensitivity (pKa), quantum yield,
and mode of operation (intensity, emission ratio, etc.).[21−24] To continuously monitor pH on a transcutaneous sensor, we have selected
luminescent dye 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt
(HPTS). HPTS has a reported pKa of 7.3
and exhibits minimal toxicity, a quantum yield of 0.82 in water, and
a linear response ranging from 6.7 to 8.7, which spans the pathophysiological
range of acidosis and alkalosis.[25,26] HPTS peak
emission intensity at 520 nm is a function of its spectral absorption
efficiency. HPTS absorbs light more efficiently at 450 nm at high
pH as compared to low pH. Conversely, HTPS absorbs 405 nm light more
efficiently at lower pH values.[27] It has
been shown that with serial light excitation at 450 and 405 nm, HPTS
can reliably measure pH through a ratiometric analysis at its peak
emission wavelength.[27,28] In an approach similar to our
own, Wencel et al. immobilized HPTS in a sol–gel placed at
the tip of a multicore fiber and calibrated pH to the ratio of 520
nm emission with dual LED excitation.[29]Numerous strategies exist to measure lactate, including colorimetric
assays, high-performance liquid chromatography, and enzyme-linked
immunosorbent assays.[30−32] One common mode of enzyme-based lactate sensing (as
used in the YSI 2300 STAT Plus Glucose and Lactate Analyzer) employs
lactate oxidase (LOX).[33] The LOX reaction
consumes both oxygen and lactate while producing hydrogen peroxide
and pyruvate. This allows lactate to be indirectly measured through
monitoring the consumption of oxygen or generation of hydrogen peroxide.[30,31] The generation of hydrogen peroxide is commonly used for electrochemical-based
LOX sensing of lactate.[33−35] Common challenges in such electrochemical
sensing include high operation voltages, dependencies on electron-transfer
mediators (which can be toxic and exhibit poor solubility), and acetaminophen
interference.[34,36,37] As an alternative to electrochemical sensing, our group and others
have published the use of a phosphorescent oxygen-sensitive dye for
continuous measurements of lactate and other analytes.[38,39] In our clinical studies, oxygen was detected by the metalloporphyrin
dye platinum(II) meso-tetraphenyl tetrabenzoporphine (PtTPTBP).[39] PtTPTBP phosphorescence is quenched by oxygen,
reducing its luminescence lifetime. This lifetime can be assessed
by determining the phase shift between excitation and emission waveforms.[40] An indirect measurement of lactate may therefore
be reported by calculating the phase shift of PtTPTBP emission in
the presence of LOX, lactate, and oxygen. This sensing scheme is adapted
here to continuously monitor lactate within a multianalyte sensor.Herein, we introduce a transcutaneous, continuous multianalyte
sensor referred to as the PALS (Figure A). PALS employs two unique sensing modalities at the
tip of a transcutaneous multianalyte sensing flexible (MSF) Sensor
to monitor pH and lactate: (1) a dual excitation, single-band detection
scheme that collects pH-sensitive light emissions and (2) a luminescence
lifetime detection scheme that captures oxygen and lactate-sensitive
light emissions (Figure B). PALS in vitro results show rapid rise time for
both pH and lactate sensing, measurement reversibility, and sensitivity
across their respective pathophysiological ranges. Furthermore, when
measuring both analytes simultaneously, measurements were shown to
be free of cross talk. An implant study in a rabbit model of hypoxemia
provides further evidence that PALS signals are reversible and in
agreement with reference values from a handheld blood gas analyzer.
The ability of PALS to optically measure pH and lactate using a transcutaneous
sensor contributes to the novelty of our technology and provides an
advantage over electrochemical sensors which are prone to chemical
species interference.
Figure 1
Schematic overview of PALS. (A) PALS comprises a wearable
unit
and a transcutaneous multianalyte sensing flexible (MSF) Sensor for
pH and lactate monitoring. (B) Exploded view of the MSF tip. LEDs
and the detector (DET) are soldered onto conductive pads of the flexible
circuit. Sensing sheets are adhered to their corresponding optoelectronic
components. The green bar above DET indicates the color filter. (C)
(left) Oxygen is monitored by analyzing the PtTPTBP light emission
phase shift using a photodetector (PD) housed in the wearable unit.
(middle) Lactate oxidase consumes both oxygen and lactate; oxygen
consumption can be used as an indirect measurement of lactate. (right)
pH is measured by ratiometric analysis of HPTS light emission.
Schematic overview of PALS. (A) PALS comprises a wearable
unit
and a transcutaneous multianalyte sensing flexible (MSF) Sensor for
pH and lactate monitoring. (B) Exploded view of the MSF tip. LEDs
and the detector (DET) are soldered onto conductive pads of the flexible
circuit. Sensing sheets are adhered to their corresponding optoelectronic
components. The green bar above DET indicates the color filter. (C)
(left) Oxygen is monitored by analyzing the PtTPTBP light emission
phase shift using a photodetector (PD) housed in the wearable unit.
(middle) Lactate oxidase consumes both oxygen and lactate; oxygen
consumption can be used as an indirect measurement of lactate. (right)
pH is measured by ratiometric analysis of HPTS light emission.
Methods
Filter-Coated
Photodetector
For the pH sensor, silicon
photodiodes (PDs) were coated with an optical filter as follows. A
plastic green bandpass filter (Primary Green Filter, Lee filters,
USA) was first cut into a 2 cm × 2 cm square. The square filter
was then placed onto the surface of a 2 mm × 1.25 mm silicon
PD (SFH2716, OSRAM Opto Semiconductors, Germany) that had been mounted
on a microscope glass slide. The edges of the filter were held in
place by two additional glass slides. A Varitemp VT-750C heat gun
(Master Appliance, USA) at a temperature setting of 250°C was
then used to melt the plastic green bandpass filter onto the PD (Figure S1).
pH Sensor Sheet
First, a 12.7 mM HPTS stock solution
was formulated by dissolving 99 mg of HPTS (MilliporeSigma, USA) in
15 mL of Milli-Q water (MilliporeSigma, 18.2 MΩ·cm at 25
°C). A total of 10 g of 45–150 μm diameter Dowex
1X8 resin beads (MilliporeSigma, USA) was then suspended in the stock
solution within a 20 mL disposable scintillation vial. This process
yields the resin bead suspension (Figure A) and allows the negatively charged sulfonate
groups on HPTS to ionically bind to the positively charged Dowex Resin.[25] A total of 500 μL of the resin bead suspension
was then added to a 1.5 mL amber glass vial along with 50 mg of poly(ethylene
glycol) dimethacrylate 8000 (PEGDMA8000, Polysciences, USA) and 12
mg of 2-hydroxy-1-(4-(2-hydroxyethoxy)phenyl)-2-methylpropan-1-one
(Irgacure 2959, Sigma-Aldrich, USA), creating the pH sensor suspension
(Figure B). PEGDMA
is considered a biocompatible material with applications including
drug delivery and cell encapsulation.[41−43]
Figure 2
HSS Fabrication. (A)
Fluorescence confocal micrograph (Olympus
Fluoview 1200) of the pH-sensitive resin bead suspension (405 nm laser
excitation, emission bandpass filter: 505–540 nm). Scale bar
= 100 μm. (B) Suspension is pipetted onto a PTFE sheet. (C)
Suspension is sandwiched between two glass slides. (D) Suspension
is polymerized, yielding the HSS. The HSS is hydrated to allow for
hydrogel swelling.
HSS Fabrication. (A)
Fluorescence confocal micrograph (Olympus
Fluoview 1200) of the pH-sensitive resin bead suspension (405 nm laser
excitation, emission bandpass filter: 505–540 nm). Scale bar
= 100 μm. (B) Suspension is pipetted onto a PTFE sheet. (C)
Suspension is sandwiched between two glass slides. (D) Suspension
is polymerized, yielding the HSS. The HSS is hydrated to allow for
hydrogel swelling.To fabricate the pH sensor
sheet (HSS), a thin circular sheet of
hydrophilic polytetrafluoroethylene (PTFE, H050A047A, 35 μm
thick, 0.50 μm pores, 47 mm diameter, Sterlitech, USA) was cut
into a 1.2 cm × 1 cm rectangle and placed onto a microscope glass
slide. PTFE was chosen as the sensing film substrate because PTFE
is biocompatible and is commonly used in dwelling commercial insulin
infusion cannulas.[44−48] A total of 40 μL of the pH sensor suspension was then pipetted
onto the cut PTFE sheet. The sheet was then sandwiched between two
glass slides (Figure C) until the pH sensor suspension uniformly coated one side of the
sheet. The pores of the PTFE sheet are 2 orders of magnitude smaller
than the resin bead diameter, preventing resin penetration into the
sheet. The coated sheet was then polymerized for 15 min using 365
nm wavelength light emitted from an 8 W dual-ultraviolet (UV) transilluminator
(VWR, USA) to produce the HSS (Figure D). Upon UV polymerization, the resin bead suspension
is encapsulated within a PEGDMA network that also polymerizes throughout
the porous network of the PTFE. Thus, all materials in contact with
the tissue are known to be biocompatible, nontoxic, and nonfouling.[49] To test for HPTS leaching out of the HSS, HSSs
were incubated in 200 μL of PBS for 8 days. Absorption of 405
nm light in the incubation solution was measured in triplicate using
a spectrophotometer (NanoDrop OneC, Thermo Scientific). Standards
were formulated at concentrations 12.7 × [100 101 10–2 10–3 10–4 10–5] mM HPTS. All but the 12.7 × 10–5 mM HPTS solution had detectable absorption. Neither
the HSS sample nor a negative control HSS lacking HPTS had detectable
absorption, indicating negligible leaching over the 8 days. The HSS
was then retrieved with tweezers and left to swell for at least 2
h in Milli-Q water within a 20 mL scintillation vial.
LOX and Oxygen
Sensor Sheets
LOX sheets were fabricated
from PTFE sheets coated with the oxygen-sensitive dye, the protein
mixture containing enzymes LOX and catalase, and pretreatment solution,
all of which are detailed in the Supporting Information. First, a 1 cm × 1 cm square of the dye-coated PTFE sheet was
excised using a razor blade. A total of 4.5 μL of pretreatment
solution was then pipetted onto each of the two microscope glass slides
(Figure A). Next,
the dye-coated PTFE sheet was sandwiched between the two glass slides
to force the pretreatment solution into the pores of the sheet. The
purpose of the pretreatment solution is to establish a porous network
within the dye-coated PTFE sheet that limits the diffusion of lactate
and oxygen. Next, two parallel double-layered strips of 25 μm-thick
Kapton tape (Tapes Master, USA) were applied to a glass slide to function
as spacers. A total of 4.5 μL of protein mixture was then pipetted
in between the spacers and onto a second slide. The pretreated dye-coated
PTFE sheet was then placed between the spacers and sandwiched between
the glass slides. While being sandwiched, the sensor sheet was polymerized
with the 8 W dual-UV transilluminator for 5 min to yield the LOX sheet
(Figure B). The oxygen
sheet was fabricated in a similar fashion except for the exclusion
of LOX and catalase in its protein mixture.
Figure 3
LOX sheet fabrication.
(A) Pretreatment solution wets the dye-coated
PTFE sheet. (B) Pretreated dye-coated PTFE sheet is sandwiched between
glass slides containing the protein mixture. Strips of Kapton tape
serve as spacers to control the membrane thickness. UV polymerization
cures the LOX sheet.
LOX sheet fabrication.
(A) Pretreatment solution wets the dye-coated
PTFE sheet. (B) Pretreated dye-coated PTFE sheet is sandwiched between
glass slides containing the protein mixture. Strips of Kapton tape
serve as spacers to control the membrane thickness. UV polymerization
cures the LOX sheet.
PALS Circuitry
PALS consists of custom-made printed
circuit boards (fabricated by OSH Park, USA) designed using Eagle
(Autodesk, USA). Essential components of the circuits are shown in Figure S2. These custom boards were manually
assembled and make up the three main subunits of PALS. The first subunit
is the MSF (Figure A). The second subunit is the wearable unit comprising three circuit
boards: (1) the integrator board for pH sensing that utilizes an IVC102
transimpedance amplifier (Texas Instruments, USA, Figure C), (2) the photodetector board
for lactate and oxygen sensing (Figure D), and (3) the connector board to connect the photodetector
and integrator boards to the MSF (Figure E). The last subunit is the backend controller
unit (shown in Figure S2) comprising a
microcontroller Teensy 3.2 (PJRC, USA) and two circuit boards: (1)
the controller board for charlieplexing and tuning the drive current
of the MSF LEDs (Figure S2A) and (2) the
IVC power supply board. Custom software was written for Teensy 3.2
to charlieplex the LEDs and acquire data, using a combination of Arduino
(Arduino, USA) with Teensyduino library (PJRC, USA) and LabView (National
Instruments, USA).
Figure 4
PALS sensing components. (A) MSF containing five on-strip
optoelectronic
components required for sensing. (B) Fully assembled MSF comprising
sensing sheets and waterproof coating. (C) Integrator board for amplifying
pH signals. (D) Photodetector board for lactate and oxygen sensing.
(E) PALS wearable unit connected to the MSF.
PALS sensing components. (A) MSF containing five on-strip
optoelectronic
components required for sensing. (B) Fully assembled MSF comprising
sensing sheets and waterproof coating. (C) Integrator board for amplifying
pH signals. (D) Photodetector board for lactate and oxygen sensing.
(E) PALS wearable unit connected to the MSF.Custom-designed housings were printed using a stereolithography
printer (Prusa SL1, Prusa Research, Czech Republic) to protect and
house the wearable unit, as illustrated in Figure . The housing unit serves to also pressure-connect
the prongs of the 5-spring battery connector (009155005852006, AVX
Corporation, USA) on the connector board to the gold pads of the MSF,
as depicted in Figure E.
MSF Fabrication
The MSF was printed and designed with
OSH Park and Eagle. The MSF comprises polyimide, which exhibits insignificant
cytotoxicity and protein adsorption when compared to PTFE and polydimethylsiloxane.[50,51] The MSF contains optoelectronic components for both pH and lactate
sensing (Figure A).
The optoelectronic components for pH sensing are a 400 nm LED (SM0603UV-400,
Bivar, USA), a 465 nm LED (APT1608QBC/G, Kingbright, USA), and a filter-coated
photodetector. Two 625 nm LEDs (APHHS1005LSECK/J3-PF, Kingbright,
USA) are used for lactate and oxygen sensing. The flex circuit is
0.135 mm thick, the detector is 0.8 mm tall, and the pH sensing sheet
is 0.035 μm thick. Collectively, the thickest portion of MSF
is 1.15 mm. Each LED spectrum is shown in Figure S3. Additionally, Video S1 shows
sequential activation of the MSF LEDs. The MSF was coated with Loctite
EA E-60NC (1:1 resin to hardener mix ratio, Henkel, Germany) for waterproofing.
The waterproof coating was left to cure overnight. The sensing sheets
were applied as described in the Supporting Information (Figure B).
Measurement
Parameters
For pH sensing, LED currents
were set to 6 mA and HSS-emitted light was sampled at 10Khz. Detection
integration times (<1 s) were tuned at the start of each experiment.
The tuning occurs in the first test solution of each in vitro experiment or following insertion for the in vivo experiment. Specifically, integration time was tuned such that the
IVC hold voltage ranged between 1 and 2 V, corresponding to 30–61%
of the total integration capacity.For lactate sensing, each
of the 625 nm LEDs was illuminated one at a time. The LEDs were driven
by a square waveform comprising 21 cycles having a peak current of
9 mA at a frequency of 5 kHz and 25% duty cycle. PtTPTBP emission
was sampled simultaneously at 500 kHz. A unique MSF was used for each
of the in vitro and in vivo experiments.
Statistical Analysis
Measurements are reported as the
mean and standard error of the mean. Statistical analyses were conducted
using a one-way analysis of variance (ANOVA) with Tukey post hoc comparison
or coefficient of variance (CV). p < 0.05 denotes
statistical significance. Prism 8 (GraphPad, USA) was used for statistical
analysis.
In Vivo Rabbit Study
The PALS implant
study was conducted with the approval of the Institutional Animal
Care and Use Committee at the University of California Irvine. A New
Zealand white rabbit was sedated with a 2:1 ratio of ketamine hydrochloride
(100 mg/mL, Ketaject, Phoenix Pharmaceutical Inc., USA): xylazine
(20 mg/mL, Anased, Lloyd Laboratories) at a dose of 37.5 mg/kg of
ketamine and 5 mg/kg of xylazine IM using a 25 gauge 5/8 inch needle.
The mixture of ketamine and xylazine was infused into the animal’s
right marginal ear vein. The animal was intubated and placed on mechanical
ventilation with a tidal volume of 50 mL per breath, respiratory rate
of 20 breaths/min, and 100% oxygen. An arterial catheter was placed
within the right femoral artery for systemic blood pressure measurements
and arterial blood gas sampling.The MSF was implanted into
the subcutaneous space of the inner left thigh of the rabbit. First,
an incision (length = 0.8 cm) was created with a scalpel. Next, Metzenbaum
dissecting scissors (Cole-Parmer, USA) were inserted inside the incision
to create a pocket by separating the skin from underlying muscle.
This pocket runs parallel to the thin skin of the rabbit and accommodates
approximately 2 cm of the MSF tip. After MSF-tip insertion, Loctite
4981 adhesive (Henkel, Germany) was applied at the incision site to
adhere the MSF onto the skin and seal the incision. The PALS wearable
unit was then placed on the skin and aligned to the MSF tip. Hypafix
adhesive (USA) was placed over the PALS wearable unit to limit sensor
movement. After baseline measurements, the PALS was disconnected,
and the animal was placed inside a sealed chamber which was then moved
into a fume hood. The animal received 800 ppm chlorine gas (Airgas,
USA) for 6 min followed by a 5 min rest period. A total of 1 mL of
100 mM trihistidyl cobinamide was then administered through the right
marginal ear vein. The animal was taken back to the surgical room,
and the PALS was reconnected to resume monitoring. At the conclusion
of the study, the animal was euthanized as per standard procedures
(1 mL of Euthasol, Virbac, USA).
Analysis of In
Vivo Data
During the
study, blood was drawn from the right femoral artery at eight time
points. Four blood draws were retrieved before and after chlorine
gas and cobinamide infusion. Blood pH and lactate concentration was
immediately assessed with an i-STAT (Abbott Laboratories, USA) using
Abbott CG4+cartridges (Abbott Laboratories, USA). PALS pH and lactate
measurements were retrospectively calibrated to the blood pH and lactate
concentrations obtained from the i-STAT with a linear regression model.
Results and Discussion
pH Sensing by Dual LED Excitation and Single-Band
Detection
The PALS uses a dual LED excitation, single-band
photodetection
scheme for measuring pH. To enable such sensing, the tip of the MSF
comprises two surface-mount LEDs to excite an HSS and a coated photodetector
to collect pH-sensitive emissions. To first determine if this is a
viable scheme, a benchtop optical system was constructed (Figure A; fabrication methods
in the Supporting Information). This system
includes surface-mount 400 nm and 465 nm dominant-wavelength LEDs
soldered onto a protoboard and a microscope objective lens that couples
emitted light to a spectrometer (Figure A). pH-sensitive spectra from an HSS in a
pH 7.6 solution were collected with serial illumination from the two
LEDs (Figure B). The
HSS emission spectrum ranges from 470 to 660 nm and has a peak value
at 520 nm. While the 400 nm LED light does not overlap the HSS emission
spectrum, the 465 nm LED does, necessitating an optical filter that
mitigates the effects of this spectral cross talk. Ideally, such a
filter should transmit the HSS emission spectrum (Figure B) and be easily applied onto
the surface of a PD. The primary green filter was selected which can
be applied onto a PD as described in the Methods. To simulate the filtering behavior of the primary green filter,
its transmission spectrum was multiplied with HSS emission spectra
(one per LED). The resulting filtered spectra show that the 465 nm
LED light has a negligible contribution to the fluorescence signal
(Figure C). To test
for pH sensitivity and reversibility, HSS spectra in solutions having
pH 7.2 or 7.6 were collected and then multiplied by the primary green
filter transmission curve. The ratio of area under the curve (AUC
Ratio: Ex465/Ex400) was determined at these two pH values. Results
indicate that the dual LED, single-band detection scheme is stable
and reversible and can be utilized as a pH optode at the tip of the
MSF (Figure D).
Figure 5
Dual LED excitation
of the HSS. (A) (left) 465 nm and 400 nm LEDs
soldered onto a protoboard and covered by an HSS; (right) HSS emission
signals are collected using a benchtop optical system for analysis.
An optical fiber routes the collected light to a spectrometer. (B)
Dual emission spectra at pH 7.6. The green spectrum shows the transmission
curve of the primary green filter. The black dotted line indicates
the HPTS peak emission wavelength. (C) HPTS emission spectra following
multiplication with the primary green filter transmission spectrum.
(D) AUC ratios for solutions of pH 7.2 and 7.6. Mean ratios were analyzed
for statistical significance. *p < 0.05.
Dual LED excitation
of the HSS. (A) (left) 465 nm and 400 nm LEDs
soldered onto a protoboard and covered by an HSS; (right) HSS emission
signals are collected using a benchtop optical system for analysis.
An optical fiber routes the collected light to a spectrometer. (B)
Dual emission spectra at pH 7.6. The green spectrum shows the transmission
curve of the primary green filter. The black dotted line indicates
the HPTS peak emission wavelength. (C) HPTS emission spectra following
multiplication with the primary green filter transmission spectrum.
(D) AUC ratios for solutions of pH 7.2 and 7.6. Mean ratios were analyzed
for statistical significance. *p < 0.05.
pH Optode
The pH optode comprises
three of the optoelectronic
elements at the tip of the MSF (Figure A). The optode is fabricated by placing an HSS at the
tip of the MSF such that it overlaps the two LEDs and filter-coated
photodetector (Figure B) as described in the Supporting Information. Photocurrents from the photodetector are amplified and converted
to a voltage using a transimpedance amplifier. pH is related to the
ratio of the voltages acquired with 465 and 400 nm LED illumination
(REx465/Ex400) after background (in the
absense of LED emission) subtraction.
Lactate Optode
The lactate optode was adapted from
our previous work. In brief, two oxygen-sensitive PtTPTBP dye sheets
are mounted on two 625 nm dominant-wavelength LEDs. One of these sheets
also contains the enzymes LOX and catalase. The working optode has
the enzyme-containing sheet, whereas the reference optode has the
enzyme-free sheet. The LEDs are illuminated in sequence, and oxygen-sensitive
dye emission is detected using a photodetector within the PALS wearable
unit (Figures and 4E).[52] Lactate is related
to the phase shift difference between the reference and working optodes.
A phase shift (ϕ) is defined as the phase difference (assessed
by Fourier transform) between the LED drive-current waveform and the
corresponding PD signal at the drive frequency. The Stern–Vollmer
equation relates oxygen partial pressure to phosphorescence lifetime
under measurement conditions (τ) and in the absence of oxygen
(τ0).[53] ϕ is related
to τ by the function tan (ϕ) = 2πfτ, where f is the modulation frequency of
LED emission.[54] This gives the equationswhere ϕw and ϕR correspond to the working and reference
optode, respectively,
ϕ0 corresponds to the absence of oxygen, Ksv is the Stern Vollmer constant, and pO2,w and pO2,R are the oxygen partial pressures at
the working and reference optode, respectively.Subtracting eq from eq yieldswhich can be rewritten
to define the sensor
signal βHere, is a proportionality constant
determined
through linear calibration in a series of lactate solutions at room
air.
pH Sensing In Vitro
To determine baseline
pH sensor stability, measurements were obtained every 30 min for 8
h in pH 7.45 solution. Unless otherwise stated, each reported steady-state
measurement is an average of 20 single-point measurements acquired
in succession. No signal drift was detected (Figure S4; CV = 0.002). The stability is due in part to the quality
of our custom LED current control circuitry (provided by the TLC driver, Figure S2A) that produces consistent LED output
power. To check the stability of both LEDs, their emission spectra
were acquired every 3 min for 30 min. Spectra show no significant
differences in AUC (CV = 0.001) or peak emission intensity (CV ≤
0.002; Figure S5). pH sensing rise time
was assessed by first incubating a sensor in a solution with pH 7.45
and then exchanging for a solution with pH 7.01. REx400/Ex465 (the ratio of detector signals under 400nm
and 465 nm excitation) was measured every 4.8 s following media exchange.
Response kinetics are described using a rising exponential plateau
model (R2 = 0.99, standard error of the
estimate (Sy.x) = 0.006) with a t90 rise time of
2.01 min (Figure A).
This rise time is short enough to capture critical physiological events
such as subdermal scalp acidosis following fetal tachycardia in high-risk
births, which occur on the time scale of minutes.[55]
Figure 6
Ratiometric pH Sensing. (A) pH sensor rise time from pH 7.45 to
7.01. The inset shows the hold voltages for each LED. (B) pH sensor
steady-state measurements in a series of pH solutions. Arrows indicate
the sequence of test solutions. (C) Calibration curve. The red shaded
region indicates a normal physiological range of pH in blood, 7.35–7.45,
while the orange and gray shaded regions indicate acidosis and alkalosis,
respectively.
Ratiometric pH Sensing. (A) pH sensor rise time from pH 7.45 to
7.01. The inset shows the hold voltages for each LED. (B) pH sensor
steady-state measurements in a series of pH solutions. Arrows indicate
the sequence of test solutions. (C) Calibration curve. The red shaded
region indicates a normal physiological range of pH in blood, 7.35–7.45,
while the orange and gray shaded regions indicate acidosis and alkalosis,
respectively.pH sensing reversibility was assessed
by sequential measurements
of solutions having a pH of 7.05, 7.22, 7.40, 7.22, and 7.05, in that
order (Figure B).
To obtain a steady measurement at each pH, the sensor was first washed
ten times with that pH solution. One-way ANOVA indicates a significant
effect across groups (p ≪ 0.01). Tukey post
hoc comparison with adjusted p-values shows significant
differences between the three unique pH solutions (p ≪ 0.01 for each comparison) but no significant differences
between repeated pH solutions (p > 0.25 for each
comparison). pH sensing sensitivity and range were assessed by exposure
to 13 solutions, with pH ranging from 6.92 to 7.59. Data follow a
Boltzmann sigmoidal model (R2 > 0.99
and Sy.x = 0.002) with a pKa of
7.16 (Figure C), which
is similar to the pKa of the HPTS dye
alone.[25] Importantly, wellness-of-fit indicates
that PALS will have clinical relevance across the pathophysiological
range including acidosis and alkalosis.[56]
Lactate Sensing In Vitro
To determine
lactate sensor stability, measurements were obtained every 30 min
for 4 h in 4 mM lactate solution. Unless otherwise stated, each reported
steady-state value is the mean of 10 measurements. No significant
signal drift was detected (Figure S6; CV
= 0.007). The stability is due in part to the inclusion of the enzyme
catalase that scavenges hydrogen peroxide, known to degrade proteins.[57,58] In this reaction, iron in catalase extracts one oxygen molecule
from hydrogen peroxide, producing a single water molecule. Then, another
oxygen molecule from a second hydrogen peroxide molecule binds to
the oxygen-bound catalase, producing a second water molecule. Molecular
oxygen is then released from the catalase.[59] Lactate sensing rise time was then assessed by changing the test
media from 0 mM (1× phosphate-buffered saline solution, PBS)
to 6 mM lactate. Phase shifts were recorded and β was calculated
every 12 s following media exchange. Response kinetics follow an exponential
plateau model (R2 = 0.95 and Sy.x = 0.01) with a t90 rise time of 3.65 min (Figure A). This rise time is comparable to commercial
continuous glucose monitors such as the Dexcom G6 and Medtronic Guardian,
which are reported to have an average rise time in vivo of 9.5 min and are effective in guiding insulin therapy.[60]
Figure 7
In vitro lactate sensing. (A) Rise time
measured
after media exchange from 0 to 6 mM lactate. The inset represents
the raw lactate and oxygen phase shift measurements. (B) β for
a series of test solutions. (C) Lactate sensor calibration and (D)
β acquired during the calibration experiment. Green lines in
A and C represent model fit to the data (equation is listed next to
each curve).
In vitro lactate sensing. (A) Rise time
measured
after media exchange from 0 to 6 mM lactate. The inset represents
the raw lactate and oxygen phase shift measurements. (B) β for
a series of test solutions. (C) Lactate sensor calibration and (D)
β acquired during the calibration experiment. Green lines in
A and C represent model fit to the data (equation is listed next to
each curve).Lactate sensing reversibility
was evaluated by sequential testing
of lactate solutions having concentrations of 0, 2.60, 4.64, 6.53,
4.64, 2.60, and 0 mM (Figure B). To obtain a steady measurement at each lactate concentration,
the sensor was first washed ten times with that lactate solution,
after which measurements were obtained. One-way ANOVA detected differences
between groups (p ≪ 0.01). Tukey post hoc
comparison with adjusted p-values shows no significant
differences between the pairing of identical lactate solutions (p > 0.87), while significant differences were found between
solutions of different lactate concentrations (p ≪
0.01). Lactate sensitivity and range were evaluated by incubation
in seven lactate solutions ranging in concentration from 0 to 14 mM.
Data follow an exponential plateau model (R2 = 0.99 and Sy.x = 0.03), showing sensitivity to
lactate from 0 to 9 mM (Figure C). Discrete β measurements are shown in Figure D. These results show that
PALS lactate sensing can distinguish between concentrations within
the pathophysiological range.
Multianalyte Sensing In Vitro
Combined
pH and lactate sensing was tested using in vitro models
of five pathophysiological conditions (Figure ). The conditions were designed to capture
sensitivity and trends of both pH and lactate in such pathologies
and to detect any interference or cross talk. A series of test solutions
with prescribed pH and lactate concentration were formulated and analyzed
using calibrated instruments (a Mettler Toledo FiveEasy pH probe and
a YSI 2300 STAT Plus Glucose and Lactate Analyzer). Solutions were
then probed using PALS in an order corresponding to each model. In
a model of hyperlactatemia, pH was maintained at 7.43 ± 0.02
while lactate was increased (Figure A). PALS signals report the increase in lactate, while
the pH signals did not significantly change (CV = 0.018). In a model
of lactic acidosis, as experienced in sepsis, solutions were formulated
to have a decrease in pH and an increase in lactate (Figure B), and PALS successfully reports
these changes. In a model of panic-disorder patients who exhibit both
respiratory alkalosis and hyperlactatemia, solutions were formulated
to have an increase in both pH and lactate concentrations.[3] PALS signals successfully reflect these increases
(Figure C). In a model
of extreme metabolic alkalosis, as can occur with chronic vomiting
and diarrhea, pH was increased while lactate was held at 3.50 mM ±
0.02 (Figure D).[61] PALS signals report the increase in pH and constant
lactate concentration (CV = 0.037). In a model of respiratory acidosis
(as seen in chronic obstructive pulmonary disease), pH was formulated
to decrease while lactate levels were held constant at 3.52 ±
0.02 (Figure E).[62] PALS signals report the decrease in pH and constant
lactate concentrations (CV = 0.016).
Figure 8
pH and lactate multianalyte sensing. A
series of solutions were
formulated to model pathological conditions. Solutions were formulated
then measured with a Mettler Toledo FiveEasy pH probe and YSI 2300
STAT Plus Glucose and Lactate Analyzer; values are shown on the horizontal
axes. Solutions were tested by PALS in order from left to right. Solutions
model: (A) hyperlactatemia, (B) lactic acidosis, (C) respiratory alkalosis
and hyperlactatemia, (D) extreme metabolic alkalosis, and (E) respiratory
acidosis.
pH and lactate multianalyte sensing. A
series of solutions were
formulated to model pathological conditions. Solutions were formulated
then measured with a Mettler Toledo FiveEasy pH probe and YSI 2300
STAT Plus Glucose and Lactate Analyzer; values are shown on the horizontal
axes. Solutions were tested by PALS in order from left to right. Solutions
model: (A) hyperlactatemia, (B) lactic acidosis, (C) respiratory alkalosis
and hyperlactatemia, (D) extreme metabolic alkalosis, and (E) respiratory
acidosis.To test for and quantify signal
interference, correlation between
lactate concentration and pH (as measured by analytical instruments)
in test solutions was first determined by aggregating values across
all experiments (Figure A–E). The Pearson’s product-moment coefficient was
low (−0.01) with a nonsignificant p-value
(0.95), confirming independence within test solutions. Next, to test
for correlations between the two sensing modalities, we aggregated
raw signals across all experiments. The Pearson’s product-moment
coefficient was low (−0.1) with a nonsignificant p-value (0.68). This insignificant correlation demonstrates the lack
of interference between PALS sensing modalities.Collectively, Figure demonstrates that
PALS does not exhibit sensing modality cross talk
and can report physiologically relevant pH and lactate changes, which
may aid clinicians in their practice of analyte-guided treatment toward
improving patient outcome.
Multianalyte Sensing In Vivo
PALS
multianalyte sensing was tested in an in vivo rabbit
model of chlorine gas poisoning and cobinamide treatment. When chlorine
gas reacts with water in the lungs, hydrochloric and hypochlorous
acid are produced. The production of these acids damages the respiratory
mucus membrane resulting in pulmonary edema and hypoxemia.[61,63] PALS should therefore detect decreasing pH and increasing lactate
values following chlorine gas administration. At the start of the
experiment, the MSF tip was implanted and connected to the wearable
unit (Figure A) for
data collection (LED serial illumination shown in Video S2). PALS signals were converted to analyte values using
retrospective linear regression (Figure S7). Both blood pH and lactate concentration decreased prior to drug
infusion as measured by PALS and intermittent i-STAT blood assays
(Figure B,C). These
decreases may be a function of the sedative chemistry and the ventilation
control. After poisoning and cobinamide treatment, PALS detected the
expected increase in lactate concentration and decrease in blood pH,
which were also in agreement with the intermittent i-STAT blood assays
(Figure B,C). The
area under the concentration-time curve ratio between PALS and i-STAT
measurements was calculated and assessed as described in Dror et al.,
following FDA guidelines.[39,64] The area under the
concentration-time curve ratio for pH (0.979) and lactate (1.084)
indicates PALS bioequivalence to the i-STAT blood analyzer in this
study. There is a difference in pH measurements between i-STAT and
PALS beginning at 110 min. PALS reports a higher pH value, with a
difference of approximately 0.025. In previous work, Bland-Altman
analysis comparing i-STAT to i-Smart and pHOx ultra-pH
meters shows that i-Stat underestimates pH (relatively) by as much
as 0.5 for values of pH < 7.3, indicating that the i-STAT may be
a source of error for the last two time points of blood comparisons.[65] Results demonstrate that PALS reports clinically
relevant pH and lactate changes and at a higher frequency than can
be offered by blood analysis alone.
Figure 9
In vivo multianalyte
sensing in a rabbit exposed
to chlorine gas. The purple region indicates when PALS measurements
were paused for chlorine gas and cobinamide administration. (A) Sensor
implanted in the subcutaneous space of the inner left thigh. Lactate
(B) and pH (C) sensing signals with intermittent blood reference values
(i-STAT).
In vivo multianalyte
sensing in a rabbit exposed
to chlorine gas. The purple region indicates when PALS measurements
were paused for chlorine gas and cobinamide administration. (A) Sensor
implanted in the subcutaneous space of the inner left thigh. Lactate
(B) and pH (C) sensing signals with intermittent blood reference values
(i-STAT).
Conclusions
We
have shown that two different photonic detection schemes on
an implanted flexible sensor can yield reliable signals for monitoring
both pH and lactate across clinically relevant ranges. Our results
suggest that PALS can be used as a one-day device, which in many cases
is sufficient in the ICU considering the ease of replacement and the
average ICU stay. As pH and lactate values are strong predictors of
mortality, the ability to provide stable and reliable measurements
of pH and lactate, on the time scale of minutes to hours, can be utilized
to guide therapy and improve patient outcome.[15,66] However, the technology should be improved before it can be used
in the clinic over extended periods. Because the process of PALS fabrication
is not controlled at the level expected for a commercial product,
we do observe differences in calibration parameters between units.
Currently, methods are being developed by our group to reduce variances
in sheet fabrication and to improve the process by which the plastic
optical filter is applied onto the photodetector. Additional engineering
development will include miniaturization of the backend electronics
to include a battery as well as wireless data control and acquisition,
which are achievable by the existing manufacturing methods. In regard
to miniaturizing the MSF, our research group has successfully reduced
the lactate optode to a width of 300 μm.[39] For the pH optode, the dimensions of the photodetector
are the limiting factor for miniaturization. In future work, we will
incorporate photodetectors having dimensions similar to the MSF LEDs,
yielding a 1/3 mm wide device.PALS can have a major impact
on patient outcomes under conditions
such as sepsis and organ failure where attentive monitoring of pH
and lactate has been reported to improve patient outcome.[1−4] Importantly, the core elements of PALS can be replicated and modified
to sense additional analytes on the MSF. For example, similar to the
operating principle of HPTS, fluorescent dyes Fura Red AM and SBFI-AM
exhibit a change in their absorbance behavior based on the concentration
of calcium and sodium, respectively.[67,68] Consequently,
our dual-excitation, single-band detection scheme could be readily
employed to continuously monitor these analytes. Moreover, our lactate
sensing scheme is generalizable to additional oxidases and their corresponding
analytes including glucose and alcohol.[69,70] The addition of these analytes can broaden the applicability of
the MSF to other medical conditions. For example, continuous monitoring
of sodium, pH, lactate, oxygen, and glucose in individuals experiencing
diabetic ketoacidosis can diagnose dehydration (loss of sodium), ketoacidosis
(high glucose and low pH), and ischemia (low oxygen and high lactate),
directing healthcare professionals toward a specific mode of intervention.[71−73] An expanded MSF could also be applicable beyond the medical field,
such as in bioreactors for protein expression, agriculture, water
management, and food industry, where sensing pH, glucose, and sodium
would provide vital information to each respective field.[74−77]
Authors: Lars W Andersen; Julie Mackenhauer; Jonathan C Roberts; Katherine M Berg; Michael N Cocchi; Michael W Donnino Journal: Mayo Clin Proc Date: 2013-10 Impact factor: 7.616
Authors: Noël Boens; Wenwu Qin; Nikola Basarić; Angel Orte; Eva M Talavera; Jose M Alvarez-Pez Journal: J Phys Chem A Date: 2006-08-03 Impact factor: 2.781
Authors: Margaret E Payne; Alla Zamarayeva; Veronika I Pister; Natasha A D Yamamoto; Ana Claudia Arias Journal: Sci Rep Date: 2019-09-23 Impact factor: 4.379